Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Financings Of The Fortnight: Bluebird Spots Brighter Skies For Gene Therapy Investment

Jul 27 2012

• By Alex Lash, Paul Bonanos, and Wendy Diller

Related Content

FDA Issues "Complete Response" On Alimera's Iluvien; Eyes More Data

Dec 30 2010

CoDa Therapeutics Closes B Round with $40 Million from Rusnano/ Domain-Led Syndicate

Jul 24 2012

Bluebird Bio Raises $60M Series D Round To Treat Rare Diseases

Jul 25 2012

EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera

Jul 20 2012

Bluebird Bio Raises $30 Million Series C To Accelerate Pipeline Development

Apr 20 2011

FDA Continues To Clarify Antibiotic Requirements With New Guidance On Complicated UTI

Mar 05 2012

Related Companies

Genetix Biotherapeutics

Alimera Sciences Inc.

CoDa Therapeutics Inc.

Takeda Pharmaceutical Co. Ltd.

Microbot Medical Inc.

Pfizer Inc.

Pfizer Inc.

NovaMedica LLC

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window